Treating Low- to Intermediate-Risk Prostate Cancer With Targeted Focal Microwave Ablation
Posted: Wednesday, August 25, 2021
According to the results of the prospective FOSTINE trial, which were published in PLOS One, organ-based tracking-fusion targeted focal microwave ablation seemed to be feasible, precise, and safe in patients with low- to intermediate-risk localized prostate cancer. Michaël Peyromaure, MD, PhD, of the Paris Descartes University, and colleagues explained that a multicenter prospective trial is under preparation to further evaluate the oncologic efficacy of this procedure.
“The organ-based tracking registration allowed us to precisely target the area of interest, thus ensuring proper placement of the microwave applicator,” the investigators commented. “As a result, our primary endpoint was reached, with 80% of patients having their index tumor entirely ablated.”
A total of 10 patients underwent transrectal organ-based tracking-fusion targeted focal microwave ablation with an 18G needle. A multiparametric prostate MRI was taken 7 days after ablation and at 6 months. The treated zone was rebiopsied 6 months after the procedure.
The median largest tumor axis was 11 mm, and the median duration of the procedure was 82 minutes. Pain and rectal bleeding were not reported in this study population; all patients were discharged the next day. Total necrosis of the index tumor on MRI was obtained in 80% of patients 7 days after ablation. One patient underwent radical prostatectomy; rebiopsy did not reveal evidence of cancer in four of the other nine patients. The IPSS (International Prostate Symptom Score), MSHQ-EjD-SF (Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form), and IIEF-5 (International Index of Erectile Function-5) scores were similar at baseline and at 6 months.
Disclosure: For full disclosures of the study authors, visit journals.plos.org.
